Trials / Completed
CompletedNCT04177810
Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer
A Phase 2 Study of Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and clinical activity of plerixafor in combination with cemiplimab in patients with metastatic pancreatic cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cemiplimab | Cemiplimab (350 mg) will be administered IV on day 1 of each cycle (21 day cycle) for up to 2 years. |
| DRUG | Plerixafor | Plerixafor (80mcg/kg/hr) will be administered as a continuous IV infusion of the first 7 days of each cycle (21 day cycle) for up to 2 years. |
Timeline
- Start date
- 2020-11-16
- Primary completion
- 2023-03-29
- Completion
- 2023-05-19
- First posted
- 2019-11-26
- Last updated
- 2024-02-23
- Results posted
- 2024-02-20
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04177810. Inclusion in this directory is not an endorsement.